Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06532565 · ClinicalTrials.gov registry record · Phase 1

Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors

A Phase 1 study of Advanced Solid Tumors, sponsored by Gilead Sciences.

Recruiting
Registry status
Phase 1
Development phase
154
Enrollment target
6
Study locations

NCT06532565 is a Phase 1 study of Advanced Solid Tumors that is actively recruiting participants, run by Gilead Sciences. The registered enrollment target is 154 participants, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06532565, a Phase 1 study of Advanced Solid Tumors, is actively recruiting participants, sponsored by Gilead Sciences.

RECRUITING
Registry status
Phase 1
Development phase
154 participants
Enrollment target
6
Study locations

Study Summary

The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as monotherapy and GS-2121 in combination with zimberelimab in participants with advanced solid tumors. * To identify the maximum tolerated dose (MTD) / maximum administered dose (MAD) and/or the recommended phase 2 dose (RP2D) of GS-2121 as monotherapy and in combination with zimberelimab in participants with advanced solid tumors.

Conditions Studied

Advanced Solid Tumors

Interventions

  • DRUG Zimberelimab
  • DRUG GS-2121

Study Locations (6)

Other

  • The Ottawa Hospital Cancer Centre - Ottawa
  • Princess Margaret Cancer Centre - Toronto

California

  • Stanford Cancer Center - Palo Alto

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Texas

  • NEXT Oncology - San Antonio

Virginia

  • NEXT Virginia - Fairfax

Trial Details

FieldValue
Enrollment Target 154 participants
Start Date 2024-07-26
Est. Completion 2028-06
Phase Phase 1

Sponsor

Gilead Sciences

504 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06532565

The ClinicalTrials.gov registry entry for NCT06532565 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 154 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 198-participant average among 144 other Advanced Solid Tumors trials with a reported enrollment target (22% lower). The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.

NCT06532565 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06532565 about?

NCT06532565 is a clinical study titled "Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors". The main goal of this first-in-human (FIH) study is to learn about the safety and dosing of GS-2121 when given alone or in combination with zimberelimab (ZIM) in participants with advanced solid tumors. The primary objectives of this study are: * To assess the safety and tolerability of GS-2121 as...

What is the current status of trial NCT06532565?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 154 participants. The study started on 2024-07-26. Estimated completion is 2028-06.

What conditions does trial NCT06532565 study?

This clinical trial studies the following conditions: Advanced Solid Tumors.

What interventions are being tested in trial NCT06532565?

The interventions under investigation include: Zimberelimab (DRUG), GS-2121 (DRUG).

Who is sponsoring clinical trial NCT06532565?

This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06532565 being conducted?

This trial has 6 study locations across California, Massachusetts, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumors

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumors

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.